FUSION CLINICAL MULTIMEDIA – Trademark Portfolio
Entity Type: 03
FUSION CLINICAL MULTIMEDIA holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 1 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include I AM FUSION MAN FUSION CLINICAL MULTIMEDIA. The owner is based in Philadelphia, PA.
777 South Broad Street, Unit 412
Philadelphia, PA 19147
Showing of trademarks Trademarks
Trademark Classifications
FUSION CLINICAL MULTIMEDIA's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does FUSION CLINICAL MULTIMEDIA have?
FUSION CLINICAL MULTIMEDIA has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does FUSION CLINICAL MULTIMEDIA file in?
FUSION CLINICAL MULTIMEDIA files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 41 (Education & Entertainment). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are FUSION CLINICAL MULTIMEDIA's most well-known trademarks?
FUSION CLINICAL MULTIMEDIA's registered trademark portfolio includes well-known marks such as I AM FUSION MAN FUSION CLINICAL MULTIMEDIA. These are among 1 currently registered trademark in the portfolio.
What is FUSION CLINICAL MULTIMEDIA's trademark registration success rate?
FUSION CLINICAL MULTIMEDIA has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.